Pfizer's RSV Shot Gets FDA Nod

An independent panel of advisors to the U.S. Food and Drug Administration (FDA) has recommended full approval of Pfizer's vaccine for protecting infants against the respiratory syncytial virus. If approved, Pfizer's ($PFE@US) vaccine would be the world's first RSV vaccine for infants. The vaccine, administered to expectant mothers in their late second or third trimester, triggers antibodies passed to the fetus, protecting RSV for the first six months of life. A phase three trial found the vaccine around 82% effective at preventing severe RSV disease during the first 90 days of life and about 70% effective during the first six months.